Switch theme
Sign up to access all valuation multiples
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
2015
131
LTM Revenue $10.3M
LTM EBITDA -$321M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
IDEAYA Biosciences has a last 12-month revenue (LTM) of $10.3M and a last 12-month EBITDA of -$321M.
In the most recent fiscal year, IDEAYA Biosciences achieved revenue of $7.0M and an EBITDA of -$323M.
IDEAYA Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See IDEAYA Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $10.3M | XXX | $7.0M | XXX | XXX | XXX |
| Gross Profit | $10.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$321M | XXX | -$323M | XXX | XXX | XXX |
| EBITDA Margin | -3108% | XXX | -4616% | XXX | XXX | XXX |
| EBIT | -$328M | XXX | -$327M | XXX | XXX | XXX |
| EBIT Margin | -3176% | XXX | -4671% | XXX | XXX | XXX |
| Net Profit | -$280M | XXX | -$274M | XXX | XXX | XXX |
| Net Margin | -2704% | XXX | -3921% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, IDEAYA Biosciences's stock price is $20.
IDEAYA Biosciences has current market cap of $1.7B, and EV of $1.1B.
See IDEAYA Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.7B | XXX | XXX | XXX | XXX | $-3.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, IDEAYA Biosciences has market cap of $1.7B and EV of $1.1B.
IDEAYA Biosciences's trades at 154.0x EV/Revenue multiple, and -3.3x EV/EBITDA.
Equity research analysts estimate IDEAYA Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
IDEAYA Biosciences has a P/E ratio of -6.2x.
See valuation multiples for IDEAYA Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 104.3x | XXX | 154.0x | XXX | XXX | XXX |
| EV/EBITDA | -3.4x | XXX | -3.3x | XXX | XXX | XXX |
| EV/EBIT | -3.3x | XXX | -3.3x | XXX | XXX | XXX |
| EV/Gross Profit | 106.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.2x | XXX | -6.4x | XXX | XXX | XXX |
| EV/FCF | -6.2x | XXX | -4.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIDEAYA Biosciences's last 12 month revenue growth is 216%
IDEAYA Biosciences's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $2.5M for the same period.
IDEAYA Biosciences's rule of 40 is -341% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IDEAYA Biosciences's rule of X is -2567% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for IDEAYA Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 216% | XXX | 187% | XXX | XXX | XXX |
| EBITDA Margin | -3108% | XXX | -4616% | XXX | XXX | XXX |
| EBITDA Growth | -2% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -341% | XXX | -4400% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2567% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4210% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 4771% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IDEAYA Biosciences acquired XXX companies to date.
Last acquisition by IDEAYA Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . IDEAYA Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was IDEAYA Biosciences founded? | IDEAYA Biosciences was founded in 2015. |
| Where is IDEAYA Biosciences headquartered? | IDEAYA Biosciences is headquartered in United States of America. |
| How many employees does IDEAYA Biosciences have? | As of today, IDEAYA Biosciences has 131 employees. |
| Who is the CEO of IDEAYA Biosciences? | IDEAYA Biosciences's CEO is Mr. Yujiro S. Hata. |
| Is IDEAYA Biosciences publicy listed? | Yes, IDEAYA Biosciences is a public company listed on NAS. |
| What is the stock symbol of IDEAYA Biosciences? | IDEAYA Biosciences trades under IDYA ticker. |
| When did IDEAYA Biosciences go public? | IDEAYA Biosciences went public in 2019. |
| Who are competitors of IDEAYA Biosciences? | Similar companies to IDEAYA Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of IDEAYA Biosciences? | IDEAYA Biosciences's current market cap is $1.7B |
| What is the current revenue of IDEAYA Biosciences? | IDEAYA Biosciences's last 12 months revenue is $10.3M. |
| What is the current revenue growth of IDEAYA Biosciences? | IDEAYA Biosciences revenue growth (NTM/LTM) is 216%. |
| What is the current EV/Revenue multiple of IDEAYA Biosciences? | Current revenue multiple of IDEAYA Biosciences is 104.3x. |
| Is IDEAYA Biosciences profitable? | Yes, IDEAYA Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of IDEAYA Biosciences? | IDEAYA Biosciences's last 12 months EBITDA is -$321M. |
| What is IDEAYA Biosciences's EBITDA margin? | IDEAYA Biosciences's last 12 months EBITDA margin is -3108%. |
| What is the current EV/EBITDA multiple of IDEAYA Biosciences? | Current EBITDA multiple of IDEAYA Biosciences is -3.4x. |
| What is the current FCF of IDEAYA Biosciences? | IDEAYA Biosciences's last 12 months FCF is -$173M. |
| What is IDEAYA Biosciences's FCF margin? | IDEAYA Biosciences's last 12 months FCF margin is -1673%. |
| What is the current EV/FCF multiple of IDEAYA Biosciences? | Current FCF multiple of IDEAYA Biosciences is -6.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
